Cyclobenzaprine HCl

DRUG3 trials

Sponsors

Takeda, University of North Carolina, Chapel Hill, Tonix Pharmaceuticals Company

Conditions

Acute Stress DisorderAcute Stress ReactionBack PainMental and Behavioural DisordersNeck PainNeurocognitive FunctionPost-traumatic StressSpasm

Phase 2

TONIX PHASE II CLINICAL STUDY IN KENYA

Active, not recruitingPACTR202012739471223

Tonix Pharmaceuticals CompanyMental and Behavioural Disorders

Start: 2022-07-01Target: 220Updated: 2026-09-14

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)

RecruitingNCT06636786

University of North Carolina, Chapel HillAcute Stress Disorder, Acute Stress Reaction, Neurocognitive Function +1

Start: 2025-03-25End: 2026-09-01Target: 180Updated: 2026-09-01

Phase 3

Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin

CompletedNCT02814565

TakedaBack Pain, Neck Pain, Spasm

Start: 2016-10-12End: 2017-03-14Updated: 2019-04-08